 - Phase II: Prior proteasome inhibitor andor Brutons tyrosine kinase inhibitors are allowed but patients may not have been exposed to the combination of proteasome inhibitor and BTK inhibitor. NOTE: Patients must have tolerated prior ibrutinib i.e., not discontinued therapy due to toxicity. 